{"id":"amocarzine","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antinematodal Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Filaricides","category":"pharmacology"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"phenthiourezine","offLabel":[],"synonyms":["amocarzine","phenthiourezine"],"timeline":[],"brandName":"Phenthiourezine","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Phenthiourezine is a key that fits into one of those locks. When it binds to the lock, it sends a signal that helps to regulate various cellular processes, leading to a therapeutic effect. However, the exact lock and signal pathway are unknown for Phenthiourezine, making it difficult to understand how it works.","oneSentence":"Phenthiourezine is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.","technicalDetail":"Phenthiourezine's mechanism of action is not well-characterized, but it is believed to involve binding to a specific protein or receptor, which triggers a cascade of downstream effects that ultimately lead to its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/185","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMOCARZINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:44:21.234569","biosimilars":[],"competitors":[],"genericName":"amocarzine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"99807U412Y","CHEBI":"CHEBI:38946","INN_ID":"6409","UMLSCUI":"C0164697","ChEMBL_ID":"CHEMBL469328","PUBCHEM_CID":"5464102","MESH_SUPPLEMENTAL_RECORD_UI":"C051744"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":22,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Phenthiourezine, also known as AMOCARZINE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to determine its potential therapeutic applications and safety profile. The lack of approved indications and patent status makes it difficult to assess its commercial viability.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}